MiMedx Group (MDXG) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 10, 2026, to elect seven directors, approve executive compensation, and ratify Deloitte & Touche LLP as the independent auditor for 2026.

• Shareholders of record as of April 13, 2026, are entitled to vote; voting can be done online, by phone, mail, or during the meeting.

• The Board recommends voting for all proposals and nominees.

• 2025 saw 20% net sales growth, strong profitability, and significant product launches and collaborations.

• The company responded to regulatory changes in Medicare reimbursement, impacting product strategy and financial guidance.

Voting matters and shareholder proposals

• Proposals include electing seven directors, advisory approval of executive compensation, and ratification of Deloitte as auditor.

• Shareholders may submit proposals or director nominations for the 2027 meeting by specified deadlines.

• Proxy access allows eligible shareholders to nominate directors in the company’s proxy materials.

Board of directors and corporate governance

• Seven directors are nominated for election; two current directors are not standing for re-election, reducing board size.

• Six of seven nominees are independent; board committees include Audit, Compensation, Nominating & Corporate Governance, and Ethics & Compliance.

• The board is led by an independent chair; a new chair will be appointed after the meeting.

• Proxy access and stock ownership guidelines are in place for directors.